echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The national insulin special centralized procurement landed in Qinghai, an average drop of 48%

    The national insulin special centralized procurement landed in Qinghai, an average drop of 48%

    • Last Update: 2022-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Qinghai Provincial Medical Insurance Bureau announced on the evening of the 30th that the national insulin special centralized procurement landed in Qinghai, with an average drop of 4
     
    According to reports, starting from May 20, 2022, public medical institutions in Qinghai Province (including medical institutions in the Qinghai Army) will fully implement the results of the sixth batch of nationally organized centralized drug procurement (insulin special project.
    The special centralized procurement of insulin covers the second- and third-generation insulins commonly used in clinical practice, including 42 varieties under 16 generic nam.
    The selected products have an average price reduction of 48%, with a maximum price reduction of 7
     
    Insulin is an important drug for the treatment of diabet.
    The number of patients is large and needs to be used for a long ti.
    The centralized procurement of insulin is the first time that the centralized drug procurement organized by the state has expanded from chemical drugs to biological dru.
    It is an important milestone in the process of centralized procurement refo.
     
    Eli Lilly's Protamine Zinc Recombinant Insulin Lispro Mixed Injection (25R), 3ml: 300 units (pre-filled), which has the largest drop in centralized procurement, has dropped from an average of 818 yuan per vial to 289 yuan per vial, depending on the patient It is estimated that using 6 sticks per month can save about 4,200 yuan in medication costs for a year, and the average daily cost is as low as less than 4 yu.
    In 2022, the first-year contract volume of insulin in Qinghai medical institutions is about 12 million pieces/bottle, which is expected to save 70 million yuan annual.
    While reducing the price, it has achieved a high degree of matching with the actual clinical needs and maintained the stability of clinical medicati.
    , To a large extent, the risk of substitution is reduc.
    At the same time, the price reduction of third-generation insulin is conducive to promoting the upgrading of insulin in clinical applicati.
     
    The Qinghai Provincial Medical Insurance Bureau stated that the bureau will do a solid job of listing selected drugs on the Internet, organizing the signing of purchase and sales contracts, linking medical insurance payment policies, promoting clinical rational drug use, and strengthening supply testi.
    At the same time, cooperate with relevant departments to further strengthen the inspection and supervision of the quality and safety of the selected insulin, production and distribution, and use, so as to meet the supply of clinical drugs, promote rational drug use, and ensure that the reform dividends benefit the majority of patien.
    (Finish)
    The Qinghai Provincial Medical Insurance Bureau announced on the evening of the 30th that the national insulin special centralized procurement landed in Qinghai, with an average drop of 4
     
    According to reports, starting from May 20, 2022, public medical institutions in Qinghai Province (including medical institutions in the Qinghai Army) will fully implement the results of the sixth batch of nationally organized centralized drug procurement (insulin special project.
    The special centralized procurement of insulin covers the second- and third-generation insulins commonly used in clinical practice, including 42 varieties under 16 generic nam.
    The selected products have an average price reduction of 48%, with a maximum price reduction of 7
     
    Insulin is an important drug for the treatment of diabet.
    The number of patients is large and needs to be used for a long ti.
    The centralized procurement of insulin is the first time that the centralized drug procurement organized by the state has expanded from chemical drugs to biological dru.
    It is an important milestone in the process of centralized procurement refo.
     
    Eli Lilly's Protamine Zinc Recombinant Insulin Lispro Mixed Injection (25R), 3ml: 300 units (pre-filled), which has the largest drop in centralized procurement, has dropped from an average of 818 yuan per vial to 289 yuan per vial, depending on the patient It is estimated that using 6 sticks per month can save about 4,200 yuan in medication costs for a year, and the average daily cost is as low as less than 4 yu.
    In 2022, the first-year contract volume of insulin in Qinghai medical institutions is about 12 million pieces/bottle, which is expected to save 70 million yuan annual.
    While reducing the price, it has achieved a high degree of matching with the actual clinical needs and maintained the stability of clinical medicati.
    , To a large extent, the risk of substitution is reduc.
    At the same time, the price reduction of third-generation insulin is conducive to promoting the upgrading of insulin in clinical applicati.
     
    The Qinghai Provincial Medical Insurance Bureau stated that the bureau will do a solid job of listing selected drugs on the Internet, organizing the signing of purchase and sales contracts, linking medical insurance payment policies, promoting clinical rational drug use, and strengthening supply testi.
    At the same time, cooperate with relevant departments to further strengthen the inspection and supervision of the quality and safety of the selected insulin, production and distribution, and use, so as to meet the supply of clinical drugs, promote rational drug use, and ensure that the reform dividends benefit the majority of patien.
    (Finish)
    The Qinghai Provincial Medical Insurance Bureau announced on the evening of the 30th that the national insulin special centralized procurement landed in Qinghai, with an average drop of 4
     
    According to reports, starting from May 20, 2022, public medical institutions in Qinghai Province (including medical institutions in the Qinghai Army) will fully implement the results of the sixth batch of nationally organized centralized drug procurement (insulin special project.
    The special centralized procurement of insulin covers the second- and third-generation insulins commonly used in clinical practice, including 42 varieties under 16 generic nam.

    The selected products have an average price reduction of 48%, with a maximum price reduction of 7
    Procurement of medicines and medicines _
     
    Insulin is an important drug for the treatment of diabet.

    The number of patients is large and needs to be used for a long ti.

    The centralized procurement of insulin is the first time that the centralized drug procurement organized by the state has expanded from chemical drugs to biological dru.

    It is an important milestone in the process of centralized procurement refo.

     
    Eli Lilly's Protamine Zinc Recombinant Insulin Lispro Mixed Injection (25R), 3ml: 300 units (pre-filled), which has the largest drop in centralized procurement, has dropped from an average of 818 yuan per vial to 289 yuan per vial, depending on the patient It is estimated that using 6 sticks per month can save about 4,200 yuan in medication costs for a year, and the average daily cost is as low as less than 4 yu.

    In 2022, the first-year contract volume of insulin in Qinghai medical institutions is about 12 million pieces/bottle, which is expected to save 70 million yuan annual.

    While reducing the price, it has achieved a high degree of matching with the actual clinical needs and maintained the stability of clinical medicati.

    , To a large extent, the risk of substitution is reduc.

    At the same time, the price reduction of third-generation insulin is conducive to promoting the upgrading of insulin in clinical applicati.

     
    The Qinghai Provincial Medical Insurance Bureau stated that the bureau will do a solid job of listing selected drugs on the Internet, organizing the signing of purchase and sales contracts, linking medical insurance payment policies, promoting clinical rational drug use, and strengthening supply testi.

    At the same time, cooperate with relevant departments to further strengthen the inspection and supervision of the quality and safety of the selected insulin, production and distribution, and use, so as to meet the supply of clinical drugs, promote rational drug use, and ensure that the reform dividends benefit the majority of patien.

    (Finish)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.